Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial

Sponsor
University Health Network, Toronto (Other)
Overall Status
Completed
CT.gov ID
NCT01881893
Collaborator
(none)
42
1
2
30
1.4

Study Details

Study Description

Brief Summary

The psychosocial development of adults with congenital heart disease (CHD) can be challenged by many issues including family overprotection, impaired peer relationships, delayed progression into independent adulthood, and difficulties with career and future planning. One-third of patients have diagnosable mood or anxiety disorders and the prevalence of depression is 3 times that of the general Canadian population. Unfortunately, most adults with CHD and significant depression or anxiety do not receive mental health treatment. Despite an increasing awareness of the unique psychosocial concerns of this patient population by both health care providers and patients, there have been no interventions targeting psychosocial outcomes in the adult CHD population. Our quantitative and qualitative research suggests that patients themselves are very interested in psychological services that target their distinctive life experiences, are provided in a group setting, and emphasize coping and resilience. The overarching aim of this proposal is to assess the feasibility of a full-scale randomized controlled trial of a group intervention aimed at improving the psychosocial functioning, quality of life, and resilience of adults with CHD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: ACHD-CARE Program
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
42 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial
Study Start Date :
Jun 1, 2013
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual Care

Patients in this arm of the study will continue to receive their regular level of care.

Experimental: ACHD-CARE Program

Group based psychosocial intervention. Educational: congenital heart disease information Behavioral: cognitive behavioral therapy Behavioral: social interactions and communication skills

Behavioral: ACHD-CARE Program
The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.

Outcome Measures

Primary Outcome Measures

  1. Psychosocial Outcome Measures: Change in depression and anxiety symptoms [Prior to randomization (baseline), immediately following the completion of the ACHD-CARE program or Usual Care period, and at three months follow-up]

    Symptoms of anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS)

Secondary Outcome Measures

  1. Psychological Outcome Measures: Social functioning [Prior to randomization (baseline), immediately following the completion of the ACHD-CARE program or Usual Care period, and at three months follow-up]

    Two metrics will be used to assess social functioning; the Social Functioning subscale of the Short Form Health Status Survey (SF-12v2) and the Enhanced Recovery in Coronary Heart Disease (ENRICHD) Social Support Inventory (ESSI).

  2. Psychosocial Outcome Measures: Resilience [Prior to randomization (baseline), immediately following the completion of the ACHD-CARE program or Usual Care period, and at three months follow-up]

    This psychosocial outcome will be measured by the Resilience Scale (RS).

  3. Psychosocial Outcome Measures: Quality of Life and health status [Prior to randomization (baseline), immediately following the completion of the ACHD-CARE program or Usual Care period, and at three months follow-up]

    The quality of life of the participants will be measured using the Satisfaction with Life Scales (SWLS) and the Linear Analogue Scale (LAS). Health status will be assessed using the SF-12v2.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Documented congenital heart disease (CHD), as confirmed by echocardiogram, cardiac catheterization, or previous surgery

  • Age greater than or equal to 18 years

  • English-language proficiency sufficient to read and complete the consent form and questionnaires and participate in an English-language group

  • No planned surgery during patient's participation in the study

  • Clinically-elevated score (i.e >=8) on the Hospital Anxiety and Depression Scale depression (HADS-D) or anxiety (HADS-A) subscale

Exclusion Criteria:
  • Current psychotherapy or pharmacotherapy

  • Significant cognitive impairment, psychosis, or personality disorder as documented in medical chart

  • Report of suicidal intent during screening

Contacts and Locations

Locations

Site City State Country Postal Code
1 Toronto Congenital Cardiac Clinic for Adults, Peter Munk Cardiac Centre, Toronto General Hospital Toronto Ontario Canada M5G 2N2

Sponsors and Collaborators

  • University Health Network, Toronto

Investigators

  • Principal Investigator: Adrienne H Kovacs, PhD, University Health Network, Toronto
  • Principal Investigator: Jane Irvine, PhD, University Health Network, York University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01881893
Other Study ID Numbers:
  • MOP 123251
First Posted:
Jun 20, 2013
Last Update Posted:
Dec 24, 2015
Last Verified:
Dec 1, 2015

Study Results

No Results Posted as of Dec 24, 2015